In the laboratory at Kanazawa University, researchers led by Professor Atsushi Mizokami have cracked open one of cancer medicine's most stubborn riddles: why some prostate cancers laugh in the face of hormone therapy and keep growing anyway. The answer lies not in the cancer cells themselves, but in a secret conversation between those cells and the healthy tissue that surrounds them—a dialogue that modern treatment inadvertently makes louder.
The specific culprit is "double-negative castration-resistant prostate cancer," or DNPC, a form so cunningly evasive that it advances without raising the alarm bells oncologists rely on. Blood tests for prostate-specific antigen, or PSA, come back normal. Neuroendocrine markers stay quiet. The cancer progresses and spreads silently, undetectable by the screening tools that catch most other prostate cancers. This stealthiness is why DNPC has emerged as one of the most lethal and treatment-resistant forms of the disease—and why its incidence has surged as more doctors use potent new androgen receptor-targeted therapies to fight more common types of prostate cancer.
A study published in Cell Death & Disease, led by Associate Professor Koji Izumi and doctoral student Taiki Kamishima alongside Mizokami, reveals the mechanical heart of this problem. When doctors aggressively suppress androgen receptor signaling through hormone therapy, they inadvertently trigger a vicious cycle between cancer cells and the fibroblasts—stromal cells—that surround them. The cancer cells begin secreting a signaling molecule called CCL2. This chemical messenger reaches out to the nearby stromal cells and instructs them to produce FGF8b, a growth factor. That FGF8b then binds to receptors on the cancer cells and activates the KRAS oncogene pathway, allowing the cancer to evade death and continue proliferating. It is, in essence, a cancer survival strategy that only becomes possible when standard treatments try to starve the tumor of its usual fuel.
The Kanazawa team demonstrated that blocking KRAS directly could disrupt this lethal conversation. When they treated prostate cancer cell lines exhibiting DNPC characteristics with a pan-KRAS inhibitor, the cancer cells stopped spreading, halted their invasion of neighboring tissue, and died as they were supposed to. The finding opens a new therapeutic avenue for patients with DNPC who currently have few effective options.
What makes this discovery particularly promising is its grounding in the real microenvironment where cancer lives. By studying the actual interplay between cancer cells and stromal cells together—rather than cancer cells in isolation—the team captured a complexity that had been invisible before. As the researchers noted, understanding these "dynamic interactions" required painstaking experimental work, but doing so revealed "the exact mechanism of KRAS signaling activation within the prostate microenvironment—a setting that much more closely mimics actual clinical conditions."
The team's next goal is ambitious: to combine KRAS inhibitors with other drugs that block FGFR or beta-catenin signaling, directly severing the communication lifeline between cancer and stromal cells. In a field where DNPC has long meant a grim prognosis, this "paradigm-shifting therapeutic strategy" represents genuine hope—a new way to fight back against cancer that has learned to hide.